Protalex — IPO Roadshow (July 2016)
26 slides from Protalex's IPO roadshow presentation, Jul 6, 2016
Slide 1: Investor Presentation July 2016
Investor Presentation July 2016
Slide 2: Disclaimer/Forward Looking Statements
Disclaimer DISCLAIMER/FORWARD LOOKING STATEMENTS This presentation highlights certain information about Protalex , Inc. (the “Company”). Statements made in this presentation stating the Company’s beliefs, intentions, and expectations are forward - looking statements. The Company’s actual results cou
Slide 3: Offering Summary
Offering Summary 3 Issuer: Protalex , Inc. Ticker: PRTX (OTC >> Nasdaq ) Total amount offered: $10.0 million Over - allotment option: 15% Use of proceeds: R&D, working capital , pay a portion of accrued interest on outstanding notes, and general corporate purposes Bookrunner : Chardan
Slide 4: Key Investment Highlights
Key Investment Highlights ▪ Immune thrombocytopenia (ITP) (>$1B) ▪ Rheumatoid Arthritis (RA) (>$22B) ▪ Other autoimmune diseases ($Bs) 4 ▪ Experienced management ▪ Strong scientific advisors ▪ Low - burn model ▪ Funded - to - date by majority shareholder, Niobe Ventures, LLC ▪ Highly - purified biol
Slide 5: Our Leadership Team
Our Leadership Team Arnold P. Kling – President; Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies James W. Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment management companies
Slide 6: Investment Thesis
Investment Thesis PRTX - 100 is a novel immunomodulatory compound with potential across various autoimmune indications ▪ ITP – an orphan disease ▪ RA – the largest autoimmune market ▪ Potential efficacy in a number of other orphan indications Six clinical studies conducted to date, each demonstr
Slide 7: Staphylococcal Protein A (SpA) and the Rationale for S. aureus-derived therapy
Staphylococcus aureus ( S. aureus ) is a leading cause of blood - stream, bone, skin, soft tissue, pulmonary and device - related infections 1 In humans, the S. aureus bacterium does not elicit a protective immune response and patients often suffer from chronic or recurrent infections 2 S. aur
Slide 8: Proposed Mechanisms of Action
PRTX - 100: Proposed Mechanisms of Action PRTX - 100: ▪ Modulates B - cells directly through their cell surface expression of a VH3 B - cell receptor ▪ Modulates Fc receptor bearing cells (monocytes, macrophages, NK cells) through binding to Fc region of IgG1, 2 and 4 PRTX - 100 has diverse acti
Slide 9: Focused on Autoimmune Diseases: Huge Markets, Unmet Needs
Focused on Autoimmune Diseases: Huge Markets, Unmet Needs Millions suffer from autoimmune diseases, including: ▪ ITP - an orphan disease ▪ RA - the largest autoimmune market Collectively, more than $23 billion spent annually on medications for RA and ITP worldwide 1 The leading biologic treatm
Slide 10: Addresses Unmet Needs in the ITP and RA Markets
PRTX - 100 Addresses Unmet Needs in the ITP and RA Markets 10 PRTX - 100 shown to be safe and well tolerated in humans; other ITP and RA drugs carry FDA black box warnings PRTX - 100 reduces immune - mediated platelet destruction; the most recently approved therapies do not Incumbent RA biolog
Slide 11: Clinical Development Milestones
Clinical Development Milestones 11 2012 2013 2014 2015 2016 2017 Immune Thrombocytopenia Explore Partnership Preclinical Rheumatoid Arthritis Phase 1b S. Africa Study 103 Phase 1b U.S. Study 104 Phase 2 EU Phase 1/2 Study 203 U.S. Phase 1/2 Study 202 Phase 1/2 Continuation Study Study 105 Additional
Slide 12: Clinical Experience
PRTX - 100: Clinical Experience Rheumatoid Arthritis (RA) 2005 – IND filed for RA 2006 – Phase 1 study completed 2007 – Second Phase 1 using PRTX - 100 with improved production/CMC processes 2010 - 2012 – Phase 1b RA Study (PRTX - 100 - 103) in South Africa; presented at ACR Annual Meeting i
Slide 13: Immune Thrombocytopenia (ITP): A Rare and Serious Disorder
Immune Thrombocytopenia (ITP): A Rare and Serious Disorder Very low blood platelet count with increased risk of bleeding and bruising Annual treatment cost of ~$60,000 for the most recently approved therapies ITP is an autoimmune disease: Afflicted people develop antibodies to their own plat
Slide 14: Inhibits Platelet Phagocytosis
PRTX - 100 Inhibits Platelet Phagocytosis In vitro studies used monocytes and platelets isolated from human blood Platelets were opsonized (coated with antibodies) and mixed with monocytes that had been treated with PRTX - 100 for 48 hours Monocytes that were not pretreated with PRTX - 100 eng
Slide 15: Effectively Treated Thrombocytopenia in a Murine Model of ITP
Chow, et al. 2010 model — involves both cellular and humoral immunity Thrombocytopenic SCID mice Mice treated on day 8 after thrombocytopenia is established PRTX - 100 raises platelet counts in a dose - dependent manner Semple , JW, et al. Poster presentation, American Society of Hematology
Slide 16: Effectively Treated Thrombocytopenia in a Murine Model of ITP
PRTX - 100 Effectively Treated Thrombocytopenia in a Murine Model of ITP 16 Thrombocytopenic SCID mice Treatments (weekly) • No treatment ( Spl ) • IVIg (positive control) • PRTX - 100 250 µg/kg • PRTX - 100 25 µg/kg • PRTX - 100 2.5 µg/kg PRTX - 100 treatment increased platelet counts in a do
Slide 17: Study 202: Adult ITP Patients with Chronic, TPO-Refractory Disease (U.S.)
Study 202: Adult ITP Patients with Chronic, TPO - Refractory Disease (U.S.) 17 PRTX - 100 1 µg/kg PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Phase 1/2 study Primary objective: • Platelet response Secondary objectives: • Safety • Response characteristics, etc. PRTX - 1
Slide 18: Study 203: Adult ITP Patients Who Failed One Prior Treatment (Europe)
Study 203: Adult ITP Patients Who Failed One Prior Treatment (Europe) 18 Screening ≤ 21 days PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Phase 1/2 study Primary objective: • Safety Secondary objectives: • Platelet response • Response duration, etc . PRTX - 100 24 µg/kg
Slide 19: Study 104: Overall Safety in RA
Study 104: Overall Safety in RA Doses of 1.5 to 12 µg/kg PRTX - 100 were well tolerated, with no observed dose - limiting toxicities No treatment - related SAEs and no requirement for expedited reports to FDA Most commonly reported AEs were fatigue and flare of RA symptoms of mild to moderate
Slide 20: Study 104: ACR50 Improvements in RA Patients on Background MTX Therapy
ACR 5 0 Response Rate 0 5 10 15 20 25 30 35 0 29 57 85 MTX +/ - PRTX - 100 Trial PRTX - 100 - 104 (1 - 4): 41 patients w active RA randomized 3:1 Baseline MTX vs MTX + PRTX - 100, five weekly i.v. doses, 1.5, 3, 6, or 12 mcg/kg Last PRTX - 100 dose at day 29 No drug - related SAEs 20 Percent
Slide 21: Study 105: Continuation Study
Study 105: Continuation Study Enrollment commenced February, 2015; last dose/visit February 2016 Open - label, multiple fixed dose trial open to Study 104 participants who indicated a desire for additional treatment Eleven patients enrolled; eight completed per protocol at single site Primar
Slide 22: Patents and Intellectual Property
Patents and Intellectual Property Patents (six issued in U.S., one in Japan, one in Europe) ▪ Initial U.S. patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE) ▪ U.S. continua
Slide 23: Protalex Milestones
Protalex Milestones x 2Q15 Complete Study 104 (U.S. Phase 1b in RA) x 2Q15 U.S. Orphan Drug Designation for PRTX - 100 in ITP x 4Q15 EU Orphan Drug Designation for PRTX - 100 in ITP x 4Q15 First dose in U.S. Phase 1/2 study (Study 202) of PRTX - 100 in ITP x 1Q16 First dose in EU Phase 1/2 study (St
Slide 24: Key Investment Highlights
Key Investment Highlights PRTX - 100 ▪ Multiple clinical indications in both orphan and large markets (ITP, RA) ▪ Potentially applicable across a broad set of autoimmune diseases ▪ Considerable cost - of - goods advantage over competitors ▪ Demonstrates superior safety profile observed in six huma
Slide 25: Financial Position
Financial Position Ticker: PRTX Exchange: OTC >> Nasdaq Current market capitalization: ~$90 million Debt (converted in next offering): ~$17.5 million (Niobe Ventures) 25
Slide 26: PRTX
PRTX PROTALEA